Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on immunotherapy, operating in the oncology and life sciences sector. The company filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 14, 2022 (accession no. 0001575872-22-001112), reporting quarterly financial results as an active public reporting entity. ESLA entered the public markets through a SPAC business combination and continued operating as a development-stage company pursuing its immunotherapy pipeline following that transaction. The November 2022 quarterly filing reflects the company's post-merger reporting obligations under SEC rules. For full filing history, deal analytics, and real-time data coverage on ESLA and the broader SPAC universe, sign up for a SpacDesk account today.